2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6273 Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China

Wei Li, Lanfang Li2, Xianming Liu, MD3, Zhao Peiqi, MD4, Zhengzi Qian5, Lihua Qiu6, Shiyong Zhou, MD7, Huilai Zhang, PhD8
1 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
2 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
3 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
4 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
5 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
6 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
7 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
8 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Background:
Novel frontline regimens have improved outcomes in diffuse large B-cell lymphoma (DLBCL), yet real-world data on their efficacy across key biological and clinical subgroups remain essential for optimizing treatment strategies. This analysis evaluated the complete remission rate (CRR) and overall response rate (ORR) of Pola-Hi-CHP in a real-world cohort of DLBCL patients, stratified by baseline characteristics and molecular subtypes.
Methods:
This retrospective study included 122 patients with DLBCL who received Hi-Pola-CHP at Tianjin Medical University Cancer Institute & Hospital, China, between March 2024 and February 2026. Responses were assessed by investigators according to the 2014 Lugano response criteria. The primary outcome was the complete response rate (CRR) at end of treatment (EOT); secondary outcomes included the overall response rate (ORR) and treatment-emergent adverse events (TEAEs). Subgroup analyses of CRR were performed based on age, Ann Arbor stage, B symptoms, cell-of-origin, International Prognostic Index (IPI) score, MYC and BCL2 expression, and extranodal involvement.
Results:
All patients completed the full six-cycle treatment regimen and received primary prophylaxis with long-acting granulocyte colony-stimulating factor (G-CSF). The overall CRR for the entire cohort (N=122) was 84.4% (95% CI: 77.0%-89.8%), with an ORR of 100.0% (95% CI: 97.0%-100.0%). Among biological subtypes, CRR was 86.3% in non-GCB group and 85.7% in GCB group. Patients with MYC or BCL2 positivity had CRRs of 83.9% and 83.1%, respectively, while those with dual-expression (DE) had a CRR of 81.8% (95% CI: 61.5%-92.7%). In the exploratory genetic subgroup analysis (n=40), high CRRs were observed across various molecular subtypes, including 90.0% in MCD, 100% in ST2, and 100% in TP53-mutated cases. The common grade ≥3 TEAEs included leukopenia and neutropenia, with no new safety signals identified.
Conclusions:
In this real-world analysis, Pola-Hi-CHP demonstrated high and remarkably consistent response rates across a wide spectrum of DLBCL patients, including those with traditionally high-risk features such as MYC/BCL2 expression and MCD mutation. The efficacy was also preserved across diverse molecular subtypes. These findings support the broad applicability of Pola-Hi-CHP as a highly effective frontline therapy for DLBCL in clinical practice.

Wei Li: No relevant conflicts of interest to declare.